.css-12qhwz2{background:url(https://backend.arctic-bioscience.com/wp-content/uploads/2021/04/cloud-download.png) no repeat;floating:left;width:24px;height : 24px;margin-right:10px;}Presentation – ABS Capital Market Update September 21, 2022 | market filter







arctic bioscience

Company Profile

Capital Markets Update, Oslo, September 21, 2022

Christer L. Valderhaug (CEO)

Develop and market pharmaceutical and nutraceutical products based on unique bioactive marine compoundsusing proprietary technology and methodology

Diary

  • Introduction and presentation of the company. Christer Valderhaug, CEO of Arctic Bioscience
  • Relief of psoriasis symptoms through herring caviar oil Dr. Kåre Steinar Tveit, Chief Physician at Haukeland University Hospital
  • Arctic Bioscience Pharmaceutical Development Program Runhild Gammelsæter, Medical Director Arctic Bioscience
  • Brain development in extremely premature babies Knut Smerud, Founder and CEO of Smerud Medical Research
  • DHA, Alpha and Omega for the Brain Ole Petter Hjelle, MD Ph.D.
  • Closing remarks and questions and answers CEO Christer Valderhaug, Medical Director Runhild Gammelsæter, CFO Jone Slinning
  • lunch and social

Two unique businesses built on a proprietary technology and IP platform

NUTRA

Premium Omega-3 products with benefits for brain, heart, eye health, prenatal and sports nutrition in global markets

PHARMACEUTICAL

Drug Candidate for Mild to Moderate Psoriasis Showing Promising Effect in Pilot Clinical Trial

Orphan drug candidate in brain development in extremely preterm infants

TECHNOLOGY / R&D

Proprietary technology platform and specialized know-how of bioactive marine compounds

Founding Story: Arctic Bioscience

2011-2016: laying the foundations

2011

2012

Arctic Bioscience is

Pharmacist

founded

product potential

discovered

2017-2022: Building the Foundation Framework for a Strong Clinical Program

2017

2019

2020

2020

pilot clinician

pilot clinician

first clinic

Scientific

trial started

Test

study results

tips of

finished

published

the ema

2021

2022

Strategic

B2C

Dr Mercola

initial public offering

HRO350

camaraderie

B2B bulk sales

the subscription is

sales pass in USA

entered with

beat NOK

launched in

3m single

euronext

Phase IIb

Kotler

20m

Norway

organize

Growth, Oslo

Climbing Nutra

2019

2019

2020

2020

globally

2019-2022: Develop the organization to prepare it for future growth

This is an excerpt from the original content. To continue reading it, access the original document here.

Disclaimer

AS Arctic Bioscience posted this content on September 21, 2022 and is solely responsible for the information contained therein. Distributed by Public, without editing or altering, the September 21, 2022 10:49:05 UTC.

Public Now 2022

All the news about ARCTIC BIOSCIENCE AS

Sales 2022 37.0M
3.58M
3.58M
Net income 2022 -37.8M
-3.66M
-3.66M
Net cash 2022 132 million
12.8M
12.8M
P/E ratio 2022 -9.23x
Performance 2022
Capitalization 330M
32.0M
32.0M
VE / Sales 2022 5.35x
VE / Sales 2023 3.32x
Number of employees 13
free float 42.6%

ARCTIC BIOSCIENCE AS GRAPHIC
Duration :
Period :



Arctic Bioscience AS Technical Analysis Chart |  market filter

Technical Analysis Trends ARCTIC BIOSCIENCE AS

short term Medium term Long-term
Trends Neutral Neutral Bearish




Evolution of the Income Statement

Sell

To buy

medium consensus HOLD
Number of analysts 1
last closing price NOK13.55
Average target price NOK15.00
Medium spread/target 10.7%


Leave a Comment